Syndax Gets FDA Fast-Track Designation for Leukemia Treatment SNDX-5613
June 28 2021 - 8:16AM
Dow Jones News
By Robb M. Stewart
Syndax Pharmaceuticals Inc. said the U.S. Food and Drug
Administration has granted fast-track designation to its leukemia
treatment SNDX-5613.
The biopharmaceutical company said Monday the designation
underscores the potential of SNDX-5613 for the treatment of adult
and pediatric patients with relapsed or refractory acute leukemias
harboring a mixed lineage leukemia rearranged or nucleophosmin
mutation.
FDA fast-track designation is designed to help development and
expedite the review of drugs to treat serious conditions with an
unmet medical need.
Syndax's shares were 5.4% higher in premarket trading, after
ending Friday at $18.36, down 17% so far in 2021.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
June 28, 2021 08:12 ET (12:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
